Drugs / Leuvectin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00005072 | Nov 2000 → Apr 2003 | prostate cancer | Vical | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00004050 | Jun 1999 → Apr 2003 | prostate cancer | Vical | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leuvectin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004050 ↗ |
| Modality | Other / unclassified | “Leuvectin to deliver this gene” NCT00004050 ↗ |
| Route | Other | “Patients receive Leuvectin intraprostatically over 10-30 seconds under ultrasound guidance on day 0” NCT00004050 ↗ |